Celebrex In Acute Gouty Arthritis Study

NCT00549549

Last updated date
Study Location
Pfizer Investigational Site
Glendale, Arizona, 85304, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gouty Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Acute gouty arthritis meeting the American College of Rheumatology (ACR) criteria for acute arthritis of primary gout;

- Onset of pain from an acute gouty arthritis attack within 48 hours prior to Screening/Baseline (Visit 1);

- A rating of moderate, severe, or extreme (2, 3, or 4, respectively) on the Patient's assessment of pain intensity in the index joint (5-point scale:0-4) at Screening/Baseline.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Diagnosis of any other type of arthritis including those types suspected of being
infectious in origin in the index joint or presence of any acute trauma of the index
joint. Patients with osteoarthritis will be included as long as it is mild or moderate
(according to investigator's criteria) and it does not affect the index joint;


- Acute polyarticular gout involving greater than 4 joints or chronic gout.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Gouty ArthritisCelebrex In Acute Gouty Arthritis Study
NCT00549549
  1. Glendale, Arizona
  2. Mesa, Arizona
  3. Paradise Valley, Arizona
  4. Peoria, Arizona
  5. Roseville, California
  6. San Diego, California
  7. San Luis Obispo, California
  8. Longmont, Colorado
  9. Northglenn, Colorado
  10. DeLand, Florida
  11. Gainesville, Florida
  12. Tampa, Florida
  13. Atlanta, Georgia
  14. Dunwoody, Georgia
  15. Rockford, Illinois
  16. Lexington, Kentucky
  17. Mt. Sterling, Kentucky
  18. Shreveport, Louisiana
  19. Shreveport, Louisiana
  20. Wheaton, Maryland
  21. Lansing, Michigan
  22. Chaska, Minnesota
  23. Columbia, Missouri
  24. Columbus, Missouri
  25. St. Louis, Missouri
  26. Omaha, Nebraska
  27. Mineola, New York
  28. Statesville, North Carolina
  29. Lyndhurst, Ohio
  30. Willoughby Hills, Ohio
  31. Duncansville, Pennsylvania
  32. Havertown, Pennsylvania
  33. Nashville, Tennessee
  34. New Tazewell, Tennessee
  35. Beaumont, Texas
  36. Beaumont, Texas
  37. Bryan, Texas
  38. Dallas, Texas
  39. San Antonio, Texas
  40. San Antonio, Texas
  41. Tyler, Texas
  42. Richmond, Virginia
  43. Milwaukee, Wisconsin
  44. Langley, British Columbia
  45. Winnipeg, Manitoba
  46. St. John's, Newfoundland and Labrador
  47. Corunna, Ontario
  48. Sarnia, Ontario
  49. Toronto, Ontario
  50. Windsor, Ontario
  51. Saskatoon, Saskatchewan
  52. Quebec,
  53. Barranquilla, Atlantico
  54. Barranquilla, Atlantico
  55. Bucaramanga, Santander
  56. Cartago,
  57. Heredia,
  58. Suwon-si, Kyeongki-do
  59. Daegu,
  60. Mexico, D.f.
  61. Mexico, DF
  62. Guadalajara, Jalisco
  63. Lima,
  64. Lima,
  65. Lima,
  66. Lipa City, Batangas
  67. Las Piñas City,
  68. Manila,
  69. Manila,
  70. Manila,
  71. Quezon City,
  72. Moscow,
  73. Petrozavodsk,
  74. St. Petersburg,
  75. St. Petersburg,
  76. Sevilla,
  77. Hualien,
  78. Taichung,
  79. Taipei,
  80. Phayathai, Bangkok
  81. Khon Kaen,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Celebrex In Acute Gouty Arthritis Study
Official Title  ICMJE A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis
Brief Summary This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Gouty
Intervention  ICMJE
  • Drug: Indomethacin
    indomethacin 50 mg three times a day (TID) for 8 days.
  • Drug: Celecoxib
    An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
  • Drug: Celecoxib
    An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
  • Drug: Celecoxib
    Celecoxib 50 mg two times a day (BID) for 8 days
Study Arms  ICMJE
  • Active Comparator: 1
    Intervention: Drug: Indomethacin
  • Experimental: 2
    Intervention: Drug: Celecoxib
  • Experimental: 3
    Intervention: Drug: Celecoxib
  • Experimental: 4
    Intervention: Drug: Celecoxib
Publications * Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 21, 2010)
402
Original Enrollment  ICMJE
 (submitted: October 24, 2007)
400
Actual Study Completion Date  ICMJE December 2009
Actual Primary Completion Date December 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Acute gouty arthritis meeting the American College of Rheumatology (ACR) criteria for acute arthritis of primary gout;
  • Onset of pain from an acute gouty arthritis attack within 48 hours prior to Screening/Baseline (Visit 1);
  • A rating of moderate, severe, or extreme (2, 3, or 4, respectively) on the Patient's assessment of pain intensity in the index joint (5-point scale:0-4) at Screening/Baseline.

Exclusion Criteria:

  • Diagnosis of any other type of arthritis including those types suspected of being infectious in origin in the index joint or presence of any acute trauma of the index joint. Patients with osteoarthritis will be included as long as it is mild or moderate (according to investigator's criteria) and it does not affect the index joint;
  • Acute polyarticular gout involving greater than 4 joints or chronic gout.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Colombia,   Costa Rica,   Korea, Republic of,   Mexico,   Peru,   Philippines,   Russian Federation,   Spain,   Taiwan,   Thailand,   United States
Removed Location Countries Italy,   United Kingdom
 
Administrative Information
NCT Number  ICMJE NCT00549549
Other Study ID Numbers  ICMJE A3191219
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director Clinical Trial Disclosure Group, Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP